Full history for every metric is available with a Kvantra account
CARGO Therapeutics, Inc. Common Stock (CRGX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 8 |
| Operating profit | $m | -187 | -239 | |||||
| Net profit | $m | - | - | -6 | -41 | -98 | -168 | -222 |
| EPS reported | $ | -3.72 | -4.68 | |||||
| Operating cashflow per share | $ | -3.11 | -2.39 | |||||
| Capex per share | $ | 0.10 | 0.03 | |||||
| FCF per share | $ | -3.21 | -2.43 | |||||
| Free cash flow | $m | -144 | -193 | |||||
| Net debt | $m | -340 | -253 | |||||
| Book value equity | $m | 360 | 238 | |||||
| Book value per share | $ | 8.01 | 4.94 | |||||
| Number of shares | m | 44.97 | 48.13 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.80 | 0.91 | |||||
| P/S LTM | x | 0.00 | 27.61 | |||||
| P/FCF LTM | x | -4.50 | -1.12 | |||||
| EV/EBITDA LTM | x | -3.82 | 0.26 | |||||
| EV/Sales LTM | x | 0.00 | -4.65 | |||||
| Earnings Yield LTM | % | -25.83% | -62.48% | |||||
| FCF Yield | % | -22.24% | -89.10% | |||||
| Quality | ||||||||
| ROE | % | -46.50% | -51.69% | |||||
| ROIC | % | -48.09% | -59.31% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.90 | -333.26 | |||||
| Net Debt/EBITDA | x | 0.22 | 1.91 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -52.39% | -116.83% | |||||
| Net debt/Equity | x | -0.94 | -1.06 | |||||
| Gross debt/equity | x | 0.08 | 0.00 | |||||
Company overview
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CARGO Therapeutics, Inc. Common Stock (CRGX)
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free